About InBios
InBios is a Healthcare company based in Seattle (United States) founded in 1996. It develops kits and rapid test strips for infectious diseases. The company has 73 employees. Its chief executive, as recorded, is Estela Raychaudhuri. InBios offers products and services including Chagas Diagnostics, Dengue Diagnostics, Strongy Detect IgG ELISA, and Scrub Typhus Diagnostics. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is InBios International, Inc. Its competitors include Inflammatix, GenMark Diagnostics and T2 Biosystems; 3 of its 3 listed competitors have raised funding.
Company details
InBios was founded in 1996 in Seattle, United States, within the in-vitro diagnostics sector. ELISA kits and rapid immunochromatographic strip assays for infectious diseases, including tuberculosis, dengue, chikungunya, and leishmaniasis, are developed, manufactured, and commercialized. Veterinary reagents are supplied, alongside contract manufacturing and assay development services. Most kits hold CE marking, with select ones cleared by the FDA or authorized for emergency use.
- Headquarters Seattle, United States
- Employees 73
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website inbios.com
- Social X
- Legal Name Inbios International, Inc.
- Latest Funding Round$1000K (USD), Grant
May 2024
- InvestorsHHS
& 1 more
- Employee Count73
Products & Services of InBios
InBios offers a comprehensive portfolio of products and services, including Chagas Diagnostics, Dengue Diagnostics, Strongy Detect IgG ELISA, and Scrub Typhus Diagnostics.
Detects Chagas disease through immunodiagnostic methods
Identifies dengue infections via rapid testing kits
Assesses strongyloidiasis with fast ELISA results
Tests for scrub typhus in high-risk areas
Funding Insights of InBios
- Total Rounds 8
- Last Round Grant — $999,997
- First Round $990,081
(Aug 2002)
- Investors Count 2
All 8 funding rounds of InBios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in InBios
InBios has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Steveandalex.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| steveandalex.org |
Investor details for InBios
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InBios
21 people are tracked at InBios (5 in leadership, 16 in team); the tracked headcount is 73.
| Name | Role | Group |
|---|---|---|
Estela Raychaudhuri | CEO & President | Leadership |
Ning Yu | Director Tumor Biology | Leadership |
Mark Evashenk | Director Clinical Operations | Leadership |
Ela Raychowdary | President | Leadership |
Brian Strehlke | Director DEA Compliance | Leadership |
Dave Edgren | Research Fellow | Team |
Gerald Warman | Hazardous Materials Specialist | Team |
Liping Soohoo | Senior Specification Specialist Jassen Supply Chain ALZA Corporation | Team |
Naiya Patel | Manufacturing Engineer II | Team |
Sandra Heinen | Associate Scientist | Team |
Mrudula Patel | Chemist | Team |
Pat Freda | Manager | Team |
Ommer Ganaway | Expert Pharmaceutical Technician | Team |
Diana Mauro | Senior Executive Admin. Assistant | Team |
Katherine Northrup (Kathy) | Stability Coordinator | Team |
Ambereen Masroor | Senior Technical Writer | Team |
Jennifer Rutkowski | Research Assistant In Drug Device Reseach And Development | Team |
Fitna Halteh | Sr. Data Specialist | Team |
Holly Renn | Senior Environmental Specialist | Team |
Sally Seaman | Clinical Data Manager | Team |
1 more people are available in the full profile.
Complete people profiles for InBios
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InBios
3 dated milestones of InBios across 28 years, from founding to its latest funding, stage changes and deals.
- Founded InBios is founded.
- Funding First funding round of $990K.
- Funding Latest funding round, Grant, of $1,000K.
Competitors of InBios
InBios has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, GenMark Diagnostics and T2 Biosystems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| t2biosystems.com | 2006 | Lexington, United States | $454.3M | 166 | Miniaturized MRI platforms for clinical diagnostics are developed. |
Detailed competitors of InBios
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InBios
The website of InBios (inbios.com) receives about 7.6K visits a month and ranks #3,023,221 among all websites worldwide, #4,009 in Biotechnology and Pharmaceuticals.
- Monthly visits7.6K
▲ 1.3% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,023,221
among all websites
- Category rank#4,009
Health · Biotechnology and Pharmaceuticals
- Bounce rate64%
- Pages per visit1.5
- Average visit22 sec
- DevicesDesktop 20% · Mobile 80%
Websites whose visitors overlap most with InBios. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| corisbio.com | 100% | 1.2K | #12,451,780 | View details | |
| fullerlabs.com | 91% | View details | |||
rapidtest.com | rapidtest.com | 88% | – | ||
| ctkbiotech.com | 84% | 15.8K | #1,803,743 | View details | |
| savyondiagnostics.com | 80% | #6,468,038 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for InBios
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as InBios (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inbios
Complete news archive for InBios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InBios
InBios was founded in 1996 and raised its 1st funding round 6 years after it was founded.
InBios is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Estela Raychaudhuri is the CEO of InBios, as recorded in our data.
InBios has 73 employees.
InBios was founded in 1996 in Seattle, United States, within the in-vitro diagnostics sector. ELISA kits and rapid immunochromatographic strip assays for infectious diseases, including tuberculosis, dengue, chikungunya, and leishmaniasis, are developed, manufactured, and commercialized. Veterinary reagents are supplied, alongside contract manufacturing and assay development services. Most kits hold CE marking, with select ones cleared by the FDA or authorized for emergency use.
InBios's top competitors include Inflammatix, GenMark Diagnostics and T2 Biosystems.
InBios offers Chagas Diagnostics, Dengue Diagnostics, Strongy Detect IgG ELISA, and Scrub Typhus Diagnostics.
InBios has 2 investors. Key investors include HHS, and Steveandalex.
InBios operates through Inbios International, Inc..